Last reviewed · How we verify
TRL345, a human monoclonal antibody — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TRL345, a human monoclonal antibody (TRL345, a human monoclonal antibody) — Trellis Bioscience LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TRL345, a human monoclonal antibody TARGET | TRL345, a human monoclonal antibody | Trellis Bioscience LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TRL345, a human monoclonal antibody CI watch — RSS
- TRL345, a human monoclonal antibody CI watch — Atom
- TRL345, a human monoclonal antibody CI watch — JSON
- TRL345, a human monoclonal antibody alone — RSS
Cite this brief
Drug Landscape (2026). TRL345, a human monoclonal antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/trl345-a-human-monoclonal-antibody. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab